4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, please visit www.4biocapital.com
Looking for a particular 4BIO Capital employee's phone or email?
The 4BIO Capital annual revenue was $4 million in 2026.
Vasily Fedorin is the COO of 4BIO Capital.
15 people are employed at 4BIO Capital.
4BIO Capital is based in London, England.
The NAICS codes for 4BIO Capital are [523, 52, 5239].
The SIC codes for 4BIO Capital are [679, 67].